Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In reference to lamborn et Al. (Neuro-oncology. 2008;10:162-170).

Literature DB >> 18725461

In reference to lamborn et Al. (Neuro-oncology. 2008;10:162-170).

Christina A Meyers, Kathleen R Lamborn, Michael D Prados.

Abstract

Mesh：

Substances：
Antineoplastic Agents

Year: 2008 PMID： 18725461 PMCID： PMC2719004 DOI： 10.1215/15228517-2008-055

Source DB: PubMed Journal: Neuro Oncol ISSN： 1522-8517 Impact factor: 12.300

Keyword Cloud
References

× No keyword cloud information.

8 in total

1. Cognitive function as a predictor of survival in patients with recurrent malignant glioma.

Authors: C A Meyers; K R Hess; W K Yung; V A Levin
Journal: J Clin Oncol Date: 2000-02 Impact factor: 44.544

2. Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression.

Authors: Christina A Meyers; Kenneth R Hess
Journal: Neuro Oncol Date: 2003-04 Impact factor: 12.300

3. Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma.

Authors: Paul D Brown; Ashley W Jensen; Sara J Felten; Karla V Ballman; Paul L Schaefer; Kurt A Jaeckle; Jane H Cerhan; Jan C Buckner
Journal: J Clin Oncol Date: 2006-12-01 Impact factor: 44.544

4. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas.

Authors: Kathleen R Lamborn; W K Alfred Yung; Susan M Chang; Patrick Y Wen; Timothy F Cloughesy; Lisa M DeAngelis; H Ian Robins; Frank S Lieberman; Howard A Fine; Karen L Fink; Larry Junck; Lauren Abrey; Mark R Gilbert; Minesh Mehta; John G Kuhn; Kenneth D Aldape; Janelle Hibberts; Pamela M Peterson; Michael D Prados
Journal: Neuro Oncol Date: 2008-03-04 Impact factor: 12.300

5. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.

Authors: Christina A Meyers; Jennifer A Smith; Andrea Bezjak; Minesh P Mehta; James Liebmann; Tim Illidge; Ian Kunkler; Jean-Michel Caudrelier; Peter D Eisenberg; Jacobus Meerwaldt; Ross Siemers; Christian Carrie; Laurie E Gaspar; Walter Curran; See-Chun Phan; Richard A Miller; Markus F Renschler
Journal: J Clin Oncol Date: 2004-01-01 Impact factor: 44.544

In reference to lamborn et Al. (Neuro-oncology. 2008;10:162-170).

1. Cognitive function as a predictor of survival in patients with recurrent malignant glioma.

2. Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression.

3. Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma.

4. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas.

5. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.

Review 6. Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors.

7. Pretreatment cognitive performance predicts survival in patients with leptomeningeal disease.

Review 8. Cognitive deficits in adult patients with brain tumours.